Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,091.52 -40.05 -1.28%
FTSE 100 6,541.61 -42.15 -0.64%
DAX 9,173.71 -165.46 -1.77%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,812.80 141.54 0.62%

Sarepta Therapeutics to Announce Third Quarter 2013 Financial Results and Corporate Update on November 12, 2013


Sarepta Therapeutics to Announce Third Quarter 2013 Financial Results and Corporate Update on November 12, 2013

CAMBRIDGE, MA -- (Marketwired) -- 10/24/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report third quarter financial results before the NASDAQ Global Market opens on Tuesday, November 12, 2013. Subsequently, at 8:00 a.m., Eastern Time (5:00 a.m., Pacific Time), Chris Garabedian, Sarepta's president and chief executive officer, and Sandy Mahatme, Sarepta's chief financial officer, will host a conference call to discuss third quarter financial results and to provide a corporate update.

The conference call may be accessed by dialing 888.895.5271 for domestic callers and 847.619.6547 for international callers. The passcode for the call is 35957586. Please specify to the operator that you would like to join the "Sarepta Third Quarter Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com.

Sarepta Investor Contact: Erin Cox 857.242.3714 ecox@sarepta.com

Sarepta Media Contact: Jim Baker 857.242.3710 jbaker@sarepta.com

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement